VJHemOnc is committed to improving our service to you

EHA 2016 | Updates from a Phase I clinical trial examining ublituximab in combination with TGR-1202

VJHemOnc is committed to improving our service to you

Owen O'Connor

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY outlines his presentation on the updates from the Phase I clinical trial examining ublituximab in combination with TGR-1202 for non-Hodgkin lymphoma (NCT02006485). Current results confirmed that the drug is well-tolerated and has a highly favorable safety profile and a continued demonstration of good efficacy in patients with indolent lymphoma, as well as patients with diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter